UniD Manufacturing are the first global Contract Development and Manufacturing Organization (CDMO) fully dedicated to micro-implants based on sustained release and polymeric formulations.

2024 is an important year for UniD Manufacturing, their first as a CDMO open to external customers, with new projects expected to be launched by the year’s end.

Ahead of CDMO Live 2024, Chief Operational Officer Pascal Bertholet shares the company’s innovative strides in micro-implant technology and their vision for a sustainable future.

“2024 marks a significant year for us as we undergo a substantial shift in our business approach.” says Pascal. The company was originally established to develop ocular implants for sister company, EyeD Pharma, but has recently expanded to offer small implants in other therapeutic areas.

“What sets us apart is our expertise in developing both the formulation and the manufacturing process for micro-implants that release active ingredients according to a specific dissolution profile. This can range from a few hours to several years. Our formulations include biodegradable, non-biodegradable, and resorbable polymers,” explains Pascal.

Read the full article on PharmaSource

Prasfarma is a company full of experts in the manufacturing of cytostatic and highly potent products (HPAPI), with a focus on oncology.

Ahead of CDMO Live we spoke to Diana Alarcón, Business Development Manager at Prasfarma to understand more about the services they offer by the Barcelona-based Contract Development & Manufacturing organisation, and how they have become Annex-1 ready .

“Prasfarma has made significant investments adapting their facilities and machinery to Annex 1 requirements for the manufacturing of sterile projects. We have expanded our facilities and increased both production and analytical departments.”

Prasfarma has a reputation for working under an agile strategy. We consider our clients as our partners.

“One of our main value is our flexibility. We work on tailor-made projects and we adapted to our customer’s needs” says Diana.

Read about their upcoming roundtable on Annex 1 here

Vitema is a fast-growing Contract Development and Manufacturing Organization (CDMO) based in Sibiu, Romania.

With one of the largest GMP-certified pharmaceutical manufacturing facilities in Europe, new management team and assets worth over €100 million, they have ambitious goals.

Ahead of CDMO Live we spoke to Diana Serban, the Head of Commercial and Business Development at Vitema.

Diana describes the company as “More than just a CDMO: we are a robust ecosystem that supports the entire pharmaceutical development lifecycle.” This includes everything from the research and development of medicines and food supplements to full-scale production. Vitema also boasts specialised capabilities for oncology products and clinical trials.

Vitema has more than 20 years experience in the pharmaceuticals market, and prides itself on its ability to assist pharmaceutical, biotech, and healthcare companies in delivering high-quality medicines and food supplements to their customers. They offer integrated services, full transparency throughout the entire manufacturing process, and highly competitive pricing data.

Read the full article